{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinum&page=2", "query": { "intervention": "Platinum", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Platinum&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-23T11:56:48.680Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03136406", "title": "QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "avelumab", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "aNK for Infusion", "type": "BIOLOGICAL" }, { "name": "ETBX-011", "type": "BIOLOGICAL" }, { "name": "GI-4000", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-08-11", "completion_date": "2019-11-01", "has_results": true, "last_update_posted_date": "2024-06-11", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136406" }, { "nct_id": "NCT05574504", "title": "Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cancer", "Urothelial Carcinoma" ], "interventions": [ { "name": "avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AdventHealth", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-05-08", "completion_date": "2028-11", "has_results": false, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05574504" }, { "nct_id": "NCT00516841", "title": "A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Peritoneal Neoplasms" ], "interventions": [ { "name": "Volociximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Facet Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2007-08", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2012-08-23", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 19, "location_summary": "Los Angeles, California • Orange, California • San Diego, California + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00516841" }, { "nct_id": "NCT07816666", "title": "Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Platinum-sensitive Relapsed Epithelial Ovarian Cancer", "Platinum-sensitive Relapsed Fallopian Tube Cancer", "Platinum-sensitive Relapsed Primary Peritoneal Cancer" ], "interventions": [ { "name": "Torvutatug samrotecan", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 600, "start_date": "2026-09-29", "completion_date": "2031-10-27", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 16, "location_summary": "Anchorage, Alaska • Columbia, Maryland • Detroit, Michigan + 12 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Albany", "state": "New York" }, { "city": "Bay Shore", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07816666" }, { "nct_id": "NCT00313456", "title": "A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tumors", "Prostate Cancer" ], "interventions": [ { "name": "Satraplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agennix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2006-03", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-05-10", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00313456" }, { "nct_id": "NCT03093922", "title": "A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Locally Advanced", "Unresectable" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-03-22", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 9, "location_summary": "Chicago, Illinois • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03093922" }, { "nct_id": "NCT02437370", "title": "Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter", "Recurrent Bladder Carcinoma", "Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter", "Regional Urothelial Carcinoma of the Renal Pelvis and Ureter", "Stage III Bladder Urothelial Carcinoma", "Stage III Urethral Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Urethral Cancer", "Urethral Urothelial Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2015-09-01", "completion_date": "2020-03-10", "has_results": false, "last_update_posted_date": "2022-10-18", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437370" }, { "nct_id": "NCT02289950", "title": "A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-Sensitive Ovarian Cancer in First Relapse" ], "interventions": [ { "name": "Farletuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 332, "start_date": "2015-03-19", "completion_date": "2020-08-13", "has_results": true, "last_update_posted_date": "2021-09-02", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 35, "location_summary": "Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02289950" }, { "nct_id": "NCT02314117", "title": "A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 645, "start_date": "2015-01-20", "completion_date": "2020-08-14", "has_results": true, "last_update_posted_date": "2021-08-26", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 25, "location_summary": "Fayetteville, Arkansas • Bakersfield, California • Fullerton, California + 19 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314117" }, { "nct_id": "NCT00109850", "title": "S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2005-05", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2015-11-18", "last_synced_at": "2026-09-23T11:56:48.680Z", "location_count": 132, "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Burlingame", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109850" } ] }